Anteris Technologies Global Corp. (ASX:AVR)
Australia
· Delayed Price · Currency is AUD | Market Cap | 734.37M |
| Revenue (ttm) | 2.87M |
| Net Income (ttm) | -141.14M |
| Shares Out | 97.27M |
| EPS (ttm) | -3.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,737 |
| Average Volume | 4,513 |
| Open | 7.78 |
| Previous Close | 7.60 |
| Day's Range | 7.55 - 7.78 |
| 52-Week Range | 4.69 - 9.79 |
| Beta | 0.55 |
| RSI | 41.00 |
| Earnings Date | May 5, 2026 |
About ASX:AVR
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tiss... [Read more]
Financial Performance
In 2025, ASX:AVR's revenue was $1.91 million, a decrease of -29.23% compared to the previous year's $2.70 million. Losses were -$94.14 million, 23.4% more than in 2024.
Financial numbers in USD Financial StatementsNews
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
MINNEAPOLIS and BRISBANE, Australia, April 28, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company commit...
Anteris Technologies (AVR) Receives Overweight Rating from Cantor Fitzgerald | AVR Stock News
Anteris Technologies (AVR) Receives Overweight Rating from Cantor Fitzgerald | AVR Stock News
Anteris Technologies Global Corp at Barclays Global Healthcare Conference Transcript
Anteris Technologies Global Corp at Barclays Global Healthcare Conference Transcript
Anteris Reports 2025 Financial Results and Provides Corporate Update
MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committ...
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to...
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committ...
Anteris Technologies Surges On Pricing Of $200Mln Public Offering
(RTTNews) - Shares of Anteris Technologies Global Corp (AVR, AVR.AX) are up over 18% at $6.82 in premarket trading on Wednesday, following the pricing of its public offering.
What Sparked Anteris Technologies (AVR) Stock Surge Over 52% After-Hours?
Anteris Technologies Global Corp. (NASDAQ: AVR) shares jumped 52.17% in after-hours trading on Tuesday, reaching $8.75, following the announcement of a major capital raise. According to Benzinga Pro ...
Anteris Prices $200 Mln Public Offering; Announces Medtronic Private Placement Up To $90 Mln
(RTTNews) - Anteris Technologies Global Corp. (AVR, AVR.AX), a medical technology company, on Tuesday, priced its public offering of 34.78 million shares at $5.75 per share, raising expected gross pro...
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committ...
Anteris Technologies (AVR) Reports Promising Results for DurAVR THV in Aortic Stenosis
Anteris Technologies (AVR) Reports Promising Results for DurAVR THV in Aortic Stenosis
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for th...
Sio Capital Management, LLC Reduces Stake in Anteris Technologies Global Corp
Sio Capital Management, LLC Reduces Stake in Anteris Technologies Global Corp
Anteris Announces Results for the Third Quarter of 2025
MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company comm...
Anteris Technologies (AVR) Reports Promising One-Year Results for DurAVR Heart Valve
Anteris Technologies (AVR) Reports Promising One-Year Results for DurAVR Heart Valve
Anteris Technologies (AVR) Advances DurAVR Heart Valve Trial
Anteris Technologies (AVR) Advances DurAVR Heart Valve Trial
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart compa...
Anteris Technologies (AVR) to Present Key Clinical Outcomes at TCT 2025
Anteris Technologies (AVR) to Present Key Clinical Outcomes at TCT 2025
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed t...
L1-backed heart medtech Anteris Technologies rakes in $39m
The placement, launched on Friday, was originally pegged at $30 million but was upsized following excess demand.
Anteris Technologies (AVR) Gains Approval for Global Heart Valve Trial in Denmark
Anteris Technologies (AVR) Gains Approval for Global Heart Valve Trial in Denmark
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed ...
Anteris Technologies (AVR) Reschedules Special Stockholders Meeting
Anteris Technologies (AVR) Reschedules Special Stockholders Meeting
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed ...
Anteris Announces Results for the Second Quarter of 2025
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to...